Human ovarian cancer cell targeting increased from ∼70% for pristine anti-HER2-SiO2 NPs, to ∼90% for HSA corona anti-HER2-SiO2 NPs.38 The HSA corona anti-HER2-SiO2 NPs had a higher affinity for human ovarian cancer cells than pristine anti-HER2-SiO2 NPs. This evidence concerns the gene ERBB2 and ovarian cancer.